[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368115-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368115-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","menopausal-hormone-therapy-assessing-associations-with-breast-and-colorectal-cancers-by-familial-risk","Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk","","Menopausal users of hormone replacement therapy (HRT) show increased breast cancer risk and decreased colorectal cancer (CRC) risk versus never-users, but the opposing effects may vary by familial risk for breast cancer and CRC. Data were harmonized from 3 cohorts and familial risk scores were derived from cancer family history, defining moderate/strong family history as a risk score ≥0.4. Among 24,486 women, results indicate effect modification by familial risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/menopausal-hormone-therapy-assessing-associations-with-breast-and-colorectal-cancers-by-familial-risk/368115/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/menopausal-hormone-therapy-assessing-associations-with-breast-and-colorectal-cancers-by-familial-risk/368115.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were familial risk scores for breast and colorectal cancer defined in the study?","Question",{"text":63,"@type":64},"The study harmonized data from three cohorts and generated separate familial risk scores from cancer family history. Moderate or strong family history was defined as a risk score of 0.4 or higher.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study find about HRT and breast cancer risk by familial risk level?",{"text":68,"@type":64},"Menopausal HRT ever use versus never use corresponded to a breast cancer hazard ratio of 1.27 (95% CI 1.11 to 1.45) for familial risk scores below 0.4, and 1.01 (95% CI 0.82 to 1.25) for scores of 0.4 or higher.",{"name":70,"@type":61,"acceptedAnswer":71},"How did colorectal cancer associations with menopausal HRT differ by familial risk?",{"text":72,"@type":64},"For CRC, the hazard ratio was 0.63 (95% CI 0.50 to 0.78) for familial risk scores below 0.4, and 1.21 (95% CI 0.73 to 2.00) for scores of 0.4 or higher, indicating differing associations by familial risk level.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368115,1790785260,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","JNCI Cancer Spectrum, 2025, 9(1), pkae121  \n[https://doi.org/10.1093/jncics/pkae121](https://doi.org/10.1093/jncics/pkae121)  \nAdvance Access Publication Date: December 3, 2024  \nBrief Communications  \nMenopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk  \nRobert J. MacInnis , PhD􀀃,1,2, Mark A. Jenkins , PhD2,3, Roger L. Milne , PhD1,2,4, Esther M. John , PhD5,6,7, Mary B. Daly, MD8, Irene L. Andrulis , PhD9, Sarah V. Colonna , MD10, Kelly-Anne Phillips , MD2,11,12, kConFab Investigators12,13,  \nLoic Le Marchand , MD, PhD14, Polly A. Newcomb, PhD15,16, Amanda I. Phipps, PhD15,16, Stephanie L. Schmit , PhD17,18, Finlay A. Macrae , MD19, Daniel D. Buchanan , PhD3,20,21, Steven Gallinger , MD9,22,23, Rish K. Pai , MD, PhD24, NiloyJ. Samadder , MD25, Graham G. Giles , PhD1,2,26, Melissa C. Southey , PhD1,4,27, John L. Hopper , PhD2, Mary Beth Terry , PhD28,29  \n1Cancer Epidemiology Division, Cancer Council Victoria, East Melbourne, VIC 3002, Australia 2Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC 3053, Australia 3Cancer Research Centre, University of Melbourne, Parkville, VIC 3053, Australia  \n4Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3800, Australia 5Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA 94305, United States 6Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA 94305, United States  \n7Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, United States 8Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA 19111, United States  \n9Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 1X5, Canada 10Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States  \n11Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia 12Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC 3010, Australia  \n13The Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), Research Department, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia  \n14Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, United States 15Epidemiology Department, University of Washington, Seattle, WA 98195, United States  \n16Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, United States 17Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44196, United States  \n18Population and Cancer Prevention Program, Case Comprehensive Cancer Center, Cleveland, OH 44106, United States 19Department of Colorectal Medicine and Genetics, Royal Melbourne Hospital, VIC 3052, Australia  \n20Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia 21Genomic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, VIC 3052, Australia  \n22PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada 23Hepatobiliary/Pancreatic Surgical Oncology Program, University Health Network, Toronto, ON M5G 2C4, Canada 24Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ 85259, United States  \n25Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, AZ 85259, United States 26Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3800, Australia  \n27Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC 3010, Australia 28Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, United S","cbCaik1pFimWeqyK","https://ap.wps.com/l/cbCaik1pFimWeqyK","pdf",871126,"English","# Abstract\n## Study design and familial risk scoring\n## Breast cancer associations\n## Colorectal cancer associations\n## Interpretation and implications","[{\"question\":\"How were familial risk scores for breast and colorectal cancer defined in the study?\",\"answer\":\"The study harmonized data from three cohorts and generated separate familial risk scores from cancer family history. Moderate or strong family history was defined as a risk score of 0.4 or higher.\"},{\"question\":\"What did the study find about HRT and breast cancer risk by familial risk level?\",\"answer\":\"Menopausal HRT ever use versus never use corresponded to a breast cancer hazard ratio of 1.27 (95% CI 1.11 to 1.45) for familial risk scores below 0.4, and 1.01 (95% CI 0.82 to 1.25) for scores of 0.4 or higher.\"},{\"question\":\"How did colorectal cancer associations with menopausal HRT differ by familial risk?\",\"answer\":\"For CRC, the hazard ratio was 0.63 (95% CI 0.50 to 0.78) for familial risk scores below 0.4, and 1.21 (95% CI 0.73 to 2.00) for scores of 0.4 or higher, indicating differing associations by familial risk level.\"}]","Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk | PDF",1790175092,15,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64b61a83131a6c12628e41b845524bbb.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfad3ebf9047acf5e62f52745984b083.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac912c0f18b9b2a3efba9ac0e81400bc.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2330b829c62ac00589a2f35d527bc08.webp",980,1287]